← All trials
NCT03347526
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2018
- Primary completion
- Mar 31, 2021
- Completion date
- Aug 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 394
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Colorado, DenverLead sponsor
- University of ColoradoOverall official - principal investigator
- Pediatric Epilepsy Research FoundationCollaborator
- West Therapeutics, IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.